Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort
Ose, J; Fortner, R-T; Schock, H; Kaaks, R; Peeters, P-H; Onland-Moret, N-C; Bueno-de-Mesquita, H-B; Weiderpass, E; Gram, I-T; Overvad, K; Tjonneland, A; Dossus, L; Fournier, A; Baglietto, L; Trichopoulou, A; Benetou, V; Trichopoulos, D; Boeing, H; Masala, G; Krogh, V; Matiello, A; Tumino, R; Popovic, M; Obon-Santacana, M; Larranaga, N; Ardanaz, E; Sánchez, M-J; Menendez, V; Chirlaque-López, María-Dolores; Travis, R-C; Khaw, K-T; Braendstedt, J; Idahl, A; Lundin, E; Rinaldi, S; Kuhn, E; Romieu, I; Gunter, M-J; Merritt, M-A; Riboli, E
Fecha:
2015-01
Resumen:
BACKGROUND: Prospective studies on insulin-like growth factor I (IGF-I) and epithelial ovarian cancer (EOC) risk are inconclusive. Data suggest risk associations vary by tumour characteristics. METHODS: We conducted a nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC) to evaluate IGF-I concentrations and EOC risk by tumour characteristics (n=565 cases). Multivariable conditional logistic regression models were used to estimate associations. RESULTS: We observed no association between IGF-I and EOC overall or by tumour characteristics. CONCLUSIONS: In the largest prospective study to date was no association between IGF-I and EOC risk. Pre-diagnostic serum IGF-I concentrations may not influence EOC risk.
Mostrar el registro completo del ítem